Haematinic

Quick links to important sections

Haematinic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Haematinic

Property Description
Active ingredient Folic Acid (Pteroylglutamic acid)
Form Tablet, Oral solution, Injectable solution
Pharmacological class Haematinic Agent, Antianemic Agent
Common use Supporting Red Blood Cell formation
Origin Synthetic form of the nutrient Folate

What Type of Medicine is a Haematinic Agent?

A Haematinic agent is a class of pharmacological substances or nutritional supplements used to support the production and maturation of blood components. This medicine's active component is Folic Acid, which is chemically known as Pteroylglutamic acid and classified as an essential Water-soluble B Vitamin (B9). Folic Acid is formally categorized as an Antianemic Agent because its primary physiological action is to prevent or correct conditions related to deficiencies in blood quality. Folic Acid is recognized for its critical status in public health. This agent is available in several high-level forms, including oral preparations such as tablets and oral solutions, as well as an injectable solution for parenteral administration.


Folic Acid Composition: Synthetic vs. Natural Folate

Folic Acid is the stable, synthetic compound used in the preparation of this Haematinic medicine, providing a vital nutrient to the body. This active ingredient is typically supplied as a single-ingredient product, though it is often included in multivitamin or prenatal formulations. It is crucial to distinguish Folic Acid from Folate, which is the general term for the naturally occurring B9 vitamins found in foods like leafy vegetables. Folic Acid is critical for metabolic pathways and proper body functions involving cell replication, and it is clinically recognized for its efficacy. While both forms serve the same ultimate function, Folic Acid is often preferred in pharmaceutical and supplemental settings due to its superior stability and consistent bioavailability. Folvite and Folicet are examples of common trade names containing this same active ingredient.


General Purpose and Role in Blood Formation

The primary general purpose of this Haematinic agent is to facilitate the complex process of haematopoiesis, or blood formation, within the bone marrow. Folic Acid is essential because it is a fundamental element required for the synthesis of DNA and RNA, the genetic blueprints necessary for all cell replication and growth. Supplying this vitamin ensures the proper maturation of Red Blood Cells (RBCs), directly supporting their ability to form fully and maintain the body's healthy capacity for oxygen transport. This nutrient serves as an essential cofactor in human metabolism.

Regulatory References

  1. Folic acid on WHO's Essential Medicines List

What side effects are possible with Haematinic?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse effects and safety constraints for the Haematinic agent Folic Acid, based strictly on government regulatory sources (e.g., U.S. FDA, EMA). This section contains no information on dosing, usage, or therapeutic benefits.


Officially Documented Adverse Reactions

Folic Acid is generally considered non-toxic. Most documented adverse reactions are classified as Rare or of Not Known frequency in official labeling. These reactions are grouped by affected body system:

System-Organ Class Examples of Reported Reactions (Rare/Not Known)
Immune & Skin Allergic sensitization, Skin rash, Pruritus (itching), Erythema (reddened skin)
Gastrointestinal Anorexia (loss of appetite), Nausea, Abdominal distention, Flatulence
Neuro-Psychiatric Altered sleep patterns, Irritability, Confusion, Impaired judgment (Reported at high doses)

Serious Adverse Reactions and Key Safety Limitations

  • Critical Warning: Obscuring Pernicious Anemia: A significant safety constraint is the potential for Folic Acid to mask the hematological symptoms of an underlying Vitamin B12 deficiency (Pernicious Anemia). This masking effect can allow potentially irreversible neurological damage to progress unchecked. Therefore, the medicine is Contraindicated for use in undiagnosed megaloblastic anemia.
  • Anaphylaxis: Severe allergic reactions, including Anaphylaxis (with shock), have been documented in isolated cases.

Population-Specific Safety Statements

  • Pregnancy: The medicine is classified as Pregnancy Category A by the FDA, indicating a low risk to the fetus based on human studies.
  • Lactation: Folic Acid is known to be excreted in breast milk.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope: Official Regulatory Information for Folic Acid

The regulatory profile for the Haematinic agent Folic Acid (Pteroylglutamic acid) documents the substance as relatively nontoxic in man, reflecting a low acute risk of fatal poisoning. The most significant regulatory concern is the risk associated with high-dose exposure.

Property Description
Documented Overdose Manifestations High chronic doses may present with gastrointestinal symptoms (e.g., anorexia, nausea, abdominal distention) and CNS effects (e.g., altered sleep patterns, confusion, impaired judgment).
Serious Outcomes High doses can mask the hematological signs of Vitamin B12 deficiency, allowing the progression of potentially irreversible neurological manifestations. Allergic sensitization, including symptoms suggestive of anaphylaxis, is also documented.

Emergency Response Statements

Property Description
Mandated Immediate Action In the event of an accidental overdose, the official regulatory instruction is to call a doctor or a poison control center immediately.
Management Context There is no specific antidote documented. Management is generally described as being symptomatic and supportive treatment, guided by medical personnel.

The regulatory documents emphasize that the primary risk lies in the critical warning that high Folic Acid intake can obscure a serious underlying deficiency. The potential for severe allergic reactions further necessitates that immediate medical attention must be sought for any accidental overexposure.

Therapeutic Uses of Haematinic

What Haematinic Treats: Main Uses and Benefits

The Haematinic agent, Folic Acid, provides therapeutic benefit by addressing critical nutritional deficits. It is applied across domains where additional symptomatic support is needed, commonly used in situations involving certain distressing symptoms. It plays a role in managing deficiency-related anemia and assists with supporting proper fetal brain and spinal cord development in pregnancy.


This medicine is considered relevant in contexts marked by increased discomfort and tension, particularly for conditions presenting with systemic or localized discomfort. Its primary therapeutic domains include treating Megaloblastic Anemia and Folate Deficiency Anemia, supporting fetal development to manage the potential for Neural Tube Defects (NTDs), and is relevant for easing associated systemic symptoms like glossitis (sore tongue) and mouth ulcers.

The medicine is applied in addressing symptom clusters that may become intense or disruptive, such as profound fatigue, persistent lethargy, and muscle weakness. This supportive therapy contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

“This agent is relevant when supportive symptom management is appropriate, especially during episodes of heightened discomfort related to deficiency.”


Quick Fact: Support for Anemia-Related Fatigue The medicine helps improve day-to-day comfort during symptomatic periods, supporting patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

The eligibility for Folic Acid (a Haematinic agent) is defined by regulatory bodies based on specific medical conditions and patient demographics.

Contraindicated Populations (Must Not Use)

Folic Acid is contraindicated in patients with:

  • Untreated Cobalamin (Vitamin B12) Deficiency or Pernicious Anemia: Use can mask the hematological symptoms of B12 deficiency while allowing irreversible neurological damage to progress.
  • Undiagnosed Megaloblastic Anemia: Should not be administered until the specific cause (folate or B12 deficiency) has been confirmed.
  • Known Hypersensitivity to the active substance or any excipients.
  • Malignant Disease (unless megaloblastic anemia is conclusively diagnosed as a folate deficiency).

Permitted and Conditional Use

Age Group / Status Official Regulatory Status
Adults, Children, Infants Use is established and permitted across all age groups for deficiency treatment.
Pregnancy and Lactation Use is permitted and recommended for pregnant females (prophylaxis) and is permitted while breastfeeding.
Conditional Restrictions Patients undergoing haemodialysis or those with certain rare hereditary problems (e.g., specific sugar intolerances) are restricted based on formulation excipients or require professional monitoring.

Eligibility is strictly determined by ruling out underlying B12 deficiency and known hypersensitivity before use.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Official regulatory information for oral iron salts (haematinics) primarily documents interactions based on chelation and absorption interference in the gastrointestinal tract, leading to specific timing-based administration requirements for many co-administered substances.

Documented Interacting Substances

Interaction Type Examples of Interacting Substances/Products
Exposure Modification (Decreased Absorption) Tetracycline and Quinolone antibiotics, Thyroid hormones (e.g., Levothyroxine), Bisphosphonates, Levodopa, Antacids (e.g., Calcium salts, Magnesium salts).
Contraindicated Combinations Injectable iron products (due to the documented risk of rapid transferrin saturation).
Pharmacodynamic Risk Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), due to an officially noted additive risk of gastrointestinal irritation.

Interaction Constraints and Timing Rules

Administration Separation: The simultaneous intake of oral iron and medications such as tetracyclines, fluoroquinolones, or levothyroxine is documented to significantly reduce the exposure of one or both drugs. Regulatory guidance necessitates separating these doses by several hours (e.g., two to six hours), depending on the specific agent, to mitigate this effect.

Food and Supplements: Dietary elements including tea, coffee, phytates (in whole grains), and dairy products are officially noted to inhibit iron absorption and should be avoided or separated from the iron dose.

Zinc Supplements are also documented as interacting with iron absorption.

Mechanism of Action

Folic Acid acts by supplying critical metabolic substrates essential for cell production and proliferation within the body. Its mechanism begins with the enzymatic activation by Dihydrofolate Reductase (DHFR), converting the precursor into the active coenzyme, Tetrahydrofolate (THF). THF is the necessary one-carbon donor that drives the subsequent synthesis of DNA building blocks.

Active THF is required for the construction of purine bases and the formation of thymidylate (dTMP). By providing necessary precursor supply, Folic Acid facilitates nucleoprotein synthesis in high-turnover tissues. This counteracts the molecular mechanism that impairs cell maturation, thereby influencing the process of erythrocyte maturation in the bone marrow.

This mechanism is conditional: THF must be continuously recycled by the B12-dependent Methionine Synthase pathway to regenerate the active cofactor pool. The Folic Acid mechanism is entirely focused on nucleic acid synthesis and provides no functional alternative for other critical B12-dependent pathways, such as those necessary for myelin sheath integrity.

Dosage and Administration Information

The administration of the haematinic agent, Folic Acid, involves established administration routes. The primary route of intake is oral, although a parenteral route (intramuscular, intravenous, or subcutaneous injection) is utilized when conditions such as severe malabsorption prevent effective oral uptake.

Standard Use and Dosing Regimens

The standard therapeutic dose for addressing folate-deficient megaloblastic anemia typically ranges from 1 mg to 5 mg once daily for adults and children over one year. Dosing frequency is generally once daily, though chronic prophylactic use, such as in cases of renal dialysis or chronic hemolytic conditions, may follow an intermittent schedule (e.g., 5 mg every few days).

Procedural Constraints

A critical procedural constraint guides the use of this medicine: the administration of doses exceeding 0.4 mg daily is associated with Vitamin B12 deficiency being ruled out or actively treated. This ensures the correct diagnostic context for the use of the drug. The injectable form may require preparation, such as dilution to 100 micrograms/mL, prior to parenteral administration.

Duration and Specific Populations

The therapeutic course for established deficiency is typically time-bound, often lasting four months or until a satisfactory blood response is achieved. Additionally, specific regimens are defined for particular populations, such as 5 mg daily for women at high risk of having a child with a Neural Tube Defect (NTD), beginning before conception and continuing through the first trimester.

Recent Clinical Evidence

Research evidence / Overview of studies for Haematinic


Evidence for use in Anemia associated with Iron Deficiency

Haematinic preparations (those containing iron) was studied for use in populations characterized by anemia associated with iron deficiency. Studies conducted were primarily short- and intermediate-term randomized controlled trials (RCTs). These research efforts examined temporary physiological imbalance related to iron levels and were applied in studies examining patient-reported experiences related to outcomes related to physical discomfort and daily functioning.

The findings describe patterns observed in the studies where monitoring of certain blood components (like hemoglobin and ferritin) during the study period reflected documented measurements of change. The research highlights changes measured over weeks or months, which contributes to understanding symptom patterns. However, variability in documented change was observed between different study populations and specific formulations studied.

What remains uncertain is the long-term impact of these preparations. Follow-up durations were limited, meaning there is limited information for long-term outcomes, including sustained changes in iron stores or overall health status beyond the research period. Also, results apply only to the populations studied, and evidence quality varies across studies due to differences in design and sample sizes.


Evidence for use in Anemia associated with Folate Deficiency

Evidence for use during Pregnancy


Long-term studies and follow-up

Evidence in special populations

What is still uncertain about Haematinic

Frequently Asked Questions (FAQ)

Common questions about Haematinic (FAQ)


Q: Is Haematinic suitable for children or adolescents?

Official information confirms that the use of this Haematinic agent is established and permitted across all age groups for deficiency treatment. Dosing guidance is provided for children in official prescribing information.


Q: Can Haematinic interact with common pain relievers like ibuprofen?

The regulatory documents for Folic Acid do not specifically list ibuprofen. However, the label for oral iron haematinics documents an officially noted additive risk of gastrointestinal irritation when taken with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class of medications that includes pain relievers.


Q: How long does a person usually stay on Haematinic?

For established deficiency, the therapeutic course is often time-bound, typically lasting around four months or until a satisfactory blood response is achieved. However, for chronic prophylactic conditions, an intermittent or long-term schedule may be used for maintenance, as described in official guidance.


Q: Is it necessary to have certain levels checked before starting Haematinic?

Official guidance emphasizes that this step is critical because the administration of Folic Acid is contingent upon Vitamin B12 deficiency being ruled out or actively treated. This is essential because Folic Acid may mask the hematological signs of an underlying B12 deficiency, which could allow potentially irreversible neurological damage to continue unchecked.


Q: What is the main difference between Haematinic and a standard iron pill?

The term 'haematinic' is a general class for medicines that help produce blood components. This specific Haematinic agent, Folic Acid, is a synthetic form of a B vitamin (B9). A standard iron pill, by contrast, contains elemental iron. Both are categorized as haematinics used to support blood production, but they are chemically distinct substances that address different underlying deficiencies.


Q: What other ingredients are in Haematinic besides the main ones?

Official drug labels list all components. Besides the active ingredient, Folic Acid, regulatory documents list inactive ingredients (excipients). These can include materials like lactose monohydrate, microcrystalline cellulose, and stearic acid, which are used to form the tablet or solution.


Q: Is Haematinic a blood builder?

Folic Acid is formally categorized as a Haematinic Agent and an Antianemic Agent in official documents. Its primary function is to provide the metabolic substrate necessary to support the production and proper maturation of Red Blood Cells (blood components) within the bone marrow.


Q: Is it normal to feel slightly nauseous after taking Haematinic?

Nausea is listed among the documented adverse reactions to Folic Acid in regulatory reports. Official documents classify most adverse reactions, including nausea, as being Rare or of Not Known frequency. Other reported gastrointestinal effects include abdominal distention and flatulence.


Q: What are some common foods or drinks that should be avoided with Haematinic?

Regulatory documents for Folic Acid note that excessive alcohol consumption may reduce the absorption and increase the elimination of the drug. Unlike oral iron products, no common food-based inhibitors like tea, coffee, or dairy products are listed as interacting with Folic Acid.


Q: Are there any specific antibiotics that interact with Haematinic?

Official documents note that some antibiotics, such as tetracycline, may suppress the growth of certain bacteria. If blood tests are conducted while these substances are being taken, this may result in false low serum and red cell folate levels in the test results.


Q: Can I drink coffee or tea when taking Haematinic?

Official regulatory documents specifically for Folic Acid do not list tea or coffee as substances that inhibit its absorption. This is in contrast to the warnings provided for oral iron salts, where these drinks are typically noted to affect absorption.


Q: What happens if I miss a dose of Haematinic?

Official patient instructions typically describe a procedure for addressing a missed dose. If a dose is missed, it is generally advised to take it as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.


Q: Is it possible to take too much Haematinic?

Folic Acid is generally considered non-toxic. However, official reports note that side effects have been observed in people receiving doses much higher than the standard therapeutic range. These effects can include neurological or psychiatric symptoms like confusion and impaired judgment.


Q: How is Haematinic different from over-the-counter supplements?

Folic Acid is available as both a prescription drug and a supplement. Regulatory information indicates that lower-dose products (e.g., 400 mu g) are often available over the counter, while higher therapeutic doses (e.g., 1 mg or 5 mg) are typically only available by prescription.


Q: What do official documents say about the safety of Haematinic for long-term use?

Regulatory documents state that formal long-term animal studies to evaluate potential cancer risk, genetic mutation risk, or effects on fertility have not been conducted. Official sources note that prolonged therapy has been associated with decreased Vitamin B12 serum levels.


Q: Does Haematinic help with general fatigue?

The symptoms of folate deficiency anemia, which this medication is used to address, commonly include general fatigue, weakness, and feeling run-down. The medication is used to address the underlying deficiency, and the correction of the deficiency is generally associated with the resolution of these types of symptoms.


Q: Is the absorption of Haematinic affected by food?

Official patient instructions usually state that Folic Acid tablets can be taken either with or without food. This indicates that food is generally not considered to significantly affect the absorption of the active ingredient.


Q: Can Haematinic be taken on an empty stomach?

Official patient instructions typically state that Folic Acid can be taken with or without food. This indicates that taking the tablet on an empty stomach is generally permissible.


Q: Is Haematinic available over the counter?

Yes, Folic Acid is available in both forms. Lower-strength products (e.g., 400 mu g) are commonly sold as over-the-counter supplements, while higher therapeutic strengths (e.g., 1 mg or 5 mg) are typically dispensed by prescription only.


Q: What information should I know about storage and handling of Haematinic?

Regulatory documents state that it should be kept in its original, tightly closed container and secured out of the reach and sight of children. It is required to be stored at controlled room temperature and protected from both light and moisture.


Q: Can Haematinic cause stomach discomfort or pain?

Official reports list gastrointestinal adverse reactions including abdominal distention and nausea, which are common sources of stomach discomfort. However, the regulatory documents do not specifically use the word 'pain' in their descriptions of side effects.


Q: Are there any mental side effects mentioned in official reports for Haematinic?

Yes, official reports for high doses mention Neuro-Psychiatric side effects. These include altered sleep patterns, irritability, confusion, impaired judgment, overactivity, excitement, and mental depression.


Q: Do any official sources mention a risk of iron overload with Haematinic?

No, this specific Haematinic agent is Folic Acid, which is a B vitamin (B9). It is not an iron product, so the risk of iron overload is not associated with this medication.


Q: How is the effectiveness of Haematinic measured by a doctor?

Effectiveness is often assessed by monitoring blood component levels to ensure the normalization of the blood picture. This assessment is used to determine if a satisfactory blood response has been achieved during the therapeutic course.


Q: If I have a food sensitivity, how can I find out if Haematinic contains that ingredient?

Official drug labels, such as the prescribing information, are required to explicitly list all inactive ingredients (excipients). Checking this list allows a person to identify if the specific formulation contains ingredients related to their food sensitivities or allergies.


Q: Does Haematinic contain any common allergens like lactose or gluten?

Some formulations of the tablets contain excipients such as lactose monohydrate (a type of sugar). Official documents caution that patients with certain rare hereditary problems, such as specific sugar intolerances, are restricted based on these formulation excipients.


Q: Are there specific symptoms that mean I should stop taking Haematinic right away?

A critical warning is the potential to mask Vitamin B12 deficiency. Signs of a rare, severe allergic reaction, such as Anaphylaxis (severe breathing difficulty or shock), are listed as adverse effects requiring immediate attention.


Q: What is the most frequently reported side effect of Haematinic in clinical studies?

Official regulatory documents classify most documented adverse reactions to Folic Acid as Rare or of Not Known frequency. This means no single side effect is officially designated as the 'most frequently reported' in the label summaries.


Q: What is the difference between Folic Acid and Folate?

Folic Acid is the stable, synthetic compound used in the preparation of this medicine. Folate is the general term for the naturally occurring B9 vitamins found in foods. Folic Acid is often preferred in pharmaceuticals due to its superior stability and consistent absorption by the body.

How should Haematinic be stored and disposed of?

How to Store and Dispose of Haematinic (Folic Acid)

Official regulatory documents define strict conditions for the storage and disposal of Folic Acid, a Haematinic agent.

Storage Requirements

Scope Element Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection Keep the product protected from light and moisture. Liquid forms, including injections, must not be frozen.
Container Keep the container tightly closed and store the medicine in its original packaging.
Child Safety Keep out of the reach and sight of children and secure all safety caps.

Disposal Instructions

Unused or expired Folic Acid should be disposed of by following local regulations or utilizing a drug take-back program. It is prohibited to flush the medication down the toilet or dispose of it in a sink or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Haematinic found in:

A-Z Index: